IP Library Granted Patent US 12,285,499
Granted Patent B2
US 12,285,499 · App. 17/942,390 · Granted Apr 29, 2025

Tissue stain and use thereof

Inventors: Mary Jo Timm (Littleton, MA); Robert G. Whalen (Willington, CT); Amy A. Cameron (Union, CT); Patrick Lee (Long Grove, IL)
Assignee: GI SUPPLY
A61K49/006A61K49/0093A61B90/39A61B2090/395
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,285,499
App. No.
17/942,390
Granted
Apr 29, 2025
Kind
B2
Abstract

Provided is a tissue staining composition containing carbon particles having a mean particle diameter less than 0.3 μm in diameter (optionally less than 0.2 μm in diameter) together with one or more agents that maintain the carbon particles in suspension (for example, an anti-settling agent and/or surfactant). In certain circumstances, the anti-settling agent may also have mucoadhesive properties. The tissue staining composition is visually dark and does not disperse rapidly when introduced into regions of tissue of interest making it ideal for marking the regions that can be visualized clearly and over prolonged periods of time via, for example, direct visualization, endoscopic or laparoscopic inspection. The invention also provides methods of making and using the tissue staining composition for marking regions of tissue of interest, for example, gastrointestinal tissue, as well as other tissues.

Claims (32)

1. A liquid tissue staining composition comprising:

deagglomerated carbon particles at a concentration of from about 0.025% to 2.0% (w/v) having a mean particle diameter of from about 0.05 μm to less than 0.2 μm;

an anti-settling agent; (ASA) at a concentration of from about 0.1% to about 1.0% (w/v), and wherein the ASA is selected from the group of hydroxyethyl cellulose, hydroxypropyl cellulose, dextran, and guar gum; and

an optional mucoadhesive agent.

2. The composition of claim 1 , wherein, when centrifuged for 60 minutes at 5,000×g, less than 50% of the carbon particles settle out of solution.

3. The composition of claim 1 , wherein the ASA is also a mucoadhesive agent.

4. The composition of claim 1 , wherein the mucoadhesive agent is present in the composition.

5. The composition of claim 4 , wherein the mucoadhesive agent is hydroxyethyl cellulose, hydroxypropyl cellulose, dextran, or guar gum.

6. The composition of claim 1 , further comprising a viscosity-increasing agent.

7. The composition of claim 6 , wherein the viscosity-increasing agent is present at a concentration of from about 5% to about 25% (w/v).

8. The composition of claim 6 , wherein the viscosity-increasing agent is selected from the group consisting of glycerol, propylene glycol, isopropylene glycol, polyethylene glycol, and cellulose.

9. The composition of claim 1 , further comprising an anti-foaming agent.

10. The composition of claim 9 , wherein the anti-foaming agent is present at a concentration of from about 0.005% to about 1.0% (w/v).

11. The composition of claim 9 , wherein the anti-foaming agent is selected from the group consisting of dimethicone and simethicone.

12. The composition of claim 1 , further comprising a surfactant.

13. The composition of claim 12 , wherein the surfactant is a non-ionic surfactant.

14. The composition of claim 12 , wherein the surfactant is present at a concentration of from about 0.01% to about 2.0% (w/V).

15. The composition of claim 12 , wherein the surfactant is selected from the group consisting of polyoxyethylene sorbitan esterified with fatty acid.

16. The composition of claim 1 , wherein the carbon particles are derived from carbon black, activated carbon, unactivated carbon or a combination thereof.

17. The composition of claim 1 , wherein the carbon particles have a level of polycyclic aromatic hydrocarbons of no greater than 0.5 ppm based on the total amount of carbon particles.

18. The composition of claim 1 , wherein the composition is terminally sterilized.

19. The composition of claim 1 , comprising:

(a) from about 0.025% to 2.0% (w/v) carbon particles; from 0.1% to about 1% (w/v) of the ASA selected from the group consisting of hydroxyethyl cellulose, hydroxypropyl cellulose, dextran, and guar gum; when present from about 5.0% to about 25% (w/v) viscosity-increasing agent; from about 0.005% to about 1.0% (w/v) anti-foaming agent; from about 0.1% to about 2.0% (w/v) surfactant; and water; or

(b) from about 0.025% to about 1.0% (w/v) carbon particles; from about 0.25% to about 1.0% (w/v) of the ASA; from about 12% to about 18% (w/v) of viscosity-increasing agent; from about 0.05% to about 0.25% (w/v) anti-foaming agent; and from about 0.7% to about 1.5% (w/v) surfactant; and water.

20. The composition of claim 1 further comprising a preservative, optionally benzyl alcohol.

21. A method of preparing the tissue staining composition of claim 1 , the method comprising:

(a) producing a composition comprising deagglomerated carbon particles having a mean particle diameter of less than 0.2 μm in diameter and optionally a surfactant; and optionally

(b) combining the composition comprising the carbon particles with an optional ASA and an optional mucoadhesive agent to produce the tissue staining composition.

22. The method of claim 21 , wherein the carbon particles in step (a) are produced by sonicating or homogenizing carbon particles having mean particle diameter of greater than 5 μm in diameter.

23. The method of claim 21 , wherein, during step (a), the composition comprises the surfactant and further comprises an anti-foaming agent.

24. A method of staining a region of tissue in a subject, the method comprising injecting the tissue staining composition of claim 1 into the region of tissue of interest in the subject in an amount effective to stain the region so as to be visible by visual inspection.

25. The method of claim 24 , wherein the tissue is tissue present in the gastrointestinal tract, bladder, lung, breast, lymph node, or central or peripheral nervous system of the subject.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 18, 2025
From: TIMM, MARY JO
To: GI SUPPLY
Reel/Frame 070242/0340 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 18, 2025
From: WHALEN, ROBERT G.; CAMERON, AMY A.
To: MYCOSCIENCE, INC.
Reel/Frame 070242/0405 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 18, 2025
From: MYCOSCIENCE, INC.
To: GI SUPPLY
Reel/Frame 070242/0429 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 18, 2025
From: LEE, PATRICK
To: GI SUPPLY
Reel/Frame 070251/0018 →
Continuity (2)
Continuation 15690178 · Aug 29, 2017
Related Publication 20230001022A1 · Jan 5, 2023
References Cited (58)
US 5122147A · Sewell, Jr. · 1992 [cited by applicant]
US 5328504A · Ohnishi · 1994 [cited by applicant]
US 5346546A · Kaliski · 1994 [cited by examiner]
US 5542948A · Weaver et al. · 1996 [cited by applicant]
US 6280702B1 · Carter · 2001 [cited by examiner]
US 6599496B2 · Carter et al. · 2003 [cited by applicant]
US 6815170B1 · Morton · 2004 [cited by examiner]
US 8709142B2 · Story et al. · 2014 [cited by applicant]
US 9034087B2 · Story et al. · 2015 [cited by applicant]
US 11452783B2 · Timm · 2022 [cited by examiner]
US 20020031474A1 · Carter et al. · 2002 [cited by applicant]
US 20130098265A1 · Story et al. · 2013 [cited by applicant]
US 20160193365A1 · De Haas · 2016 [cited by applicant]
CN 1458185A · 2003 [cited by applicant]
CN 1935263A · 2007 [cited by applicant]
CN 104971365A · 2015 [cited by applicant]
CN 105998065A · 2016 [cited by applicant]
JP H06294081A · 1994 [cited by applicant]
JP 2005521707A · 2005 [cited by applicant]
JP 2007114129A · 2007 [cited by applicant]
JP 2007262062A · 2007 [cited by applicant]
WO WO9944638A1 · 1999 [cited by applicant]
WO WO2007024429A2 · 2007 [cited by applicant]
WO WO20070115291A2 · 2007 [cited by applicant]
“Pointer” Endoscopic Marker ADDOBIO Product Brochure; 43 pages (see pp. 7-8) which Applicant believes may have been distributed by Osteonic Co., Ltd. (see http://osteonic.com/eng/product/product_list_view.php?M1=7&M2-72… [cited by applicant]
Butyl Acrylate MSDS, BASF, The Chemical Company, Revision Date Oct. 26, 2005, 8 pages. [cited by applicant]
Cilurzo et al. (2011) “Injectability Evaluation: An Open Issue,” AAPS PharmSciTech, 12(2): 604-609. [cited by applicant]
Combined Search and Examination Report under Sections 17 & 18(3) dated Mar. 15, 2018 in GB Patent Application No. 1802374.7, 6 pages. [cited by applicant]
Fung, et al., Introduction to Bioengineering World Scientific Publishing, p. 163, (Year: 2001). [cited by applicant]
Glycidyl methacrylate MSDS, Sigma-Aldrich.com, Revision Date Jun. 23, 2015, 9 pages [cited by applicant]
Great Britain Patent Application No. 1802374.7, Examination Report, dated Jul. 23, 2019. [cited by applicant]
International Search Report and Written Opinion in PCT/US2018/016227 dated Apr. 19, 2018, 12 pages. [cited by applicant]
Methyl methacrylate MSDS, Science Lab.com, created Oct. 10, 2005, 5 pages. [cited by applicant]
Saraswathi et al. (2013) “Polymers in Mycoadhesive Drug Delivery System—Latest Updates,” Int. J. Pharm, Sci. 5(3): 423-430. [cited by applicant]
SpotTM Endoscopic Marker, Instructions for use accessed on the internet at https://www.gi-supply.com/wp-content/uploads/2017/05/Spot-IFU-G44-006-Rev-10-no-crop.pdf; 1page, printed Nov. 2017. [cited by applicant]
SpotTM Endoscopic Marker, product literature accessed on the internet at <https://www.gi-supply.com/wp-content/uploads/2017/07/Spot-Sample-Booklet-Our-Story-G-1301-03.pdf>; 12 pages, printed Nov. 2017. [cited by applicant]
Tscharnuter et al. (2011) “ASTM Carbon Black Reference Materials: Particle Sizing Using a Brookhaven Instruments BI-DCP, Disc Centrifuge Photosedimentometer,” Brookhaven Instruments Corporation, 1: 1-10.2011, downloaded… [cited by applicant]
US Ink “How Does a Densitometer Work?” vol. IX, pp. 1-6, downloaded from http://www.sunchemical.com/download/how-does-a-densitometer-work/ on Jan. 17, 2018. [cited by applicant]
Wu, et al., “Sentinel Lymph Node Detection Using Carbon Nanoparticles in Patients with Early Breast Cancer,” PLOS One, (2015), vol. 10, No. 8, pp. 1-12. [cited by applicant]
Xie, P. et al., Drug-loaded carbon nanoparticle suspension injection: drug selection, releasing behavior, in vitro cytotoxicity and in vivo lymph node targeting, Journal of Nanoscience and Nanotechnology. 2016, vol. 16,… [cited by applicant]
Yu et al. (2014) “Chapter 2. Mucoadhesion and Characterization of Mucoadhesive Properties,” Mucosal Delivery of Biopharmaceuticals, pp. 35-44, J. das Neves, B. Sarmento (eds.). [cited by applicant]
SPOT Endoscopic Marker, Safety Data Sheet, GI Supply, Camp Hill, Pennsylvania, 7 pp (effective date Oct. 29, 2015). [cited by applicant]
Bonnard et al., Noir de carbone, CAS No. 1333-86-4, Institut National de Recherche et de Sécurite, 8 pp. (2007). [cited by applicant]
European Patent Application No. 18753763.4, Extended European Search Report, dated Dec. 7, 2020. [cited by applicant]
Japanese Patent Application No. 2019-507908, Office Action, issued Nov. 2, 2021. [cited by applicant]
“Black Eye” Endoscopic Marker Product Brochure (dated 2012) accessed on the internet at http://www.innomedicus.com/Files/products/gastro%20-%2Oblack%20eye/015_30_ifu - black_eye_v03_rev1.pdf; 1 page, printed Nov. 2017. [cited by applicant]
“Black Eye” Endoscopic Marker Product Brochure (dated 2012) accessed on the internet at http://www.innomedicus.com/Files/products/gastro%20-%2Oblack%20eye/015_30_pi - black_eye_v130305tsec.pdf; 2 pages, printed Nov. 201… [cited by applicant]
“Endomark” Endoscopic Marker, product literature (dated Aug. 2015) accessed on the internet at http://www.pmtcorp.com/pdfs/2015_PMT_Endomark_Sell_Sheet.pdf; 2 pages, printed Jan. 23, 2018. [cited by applicant]
“Insights on Carbon Black Fundamentals,” Modern Dispersions, Inc., downloaded from http://www.moderndispersions.com/carbonblack.html on Jan. 26, 2018. [cited by applicant]
“Pointer” Endoscopic Marker ADDOBIO Product Brochure; 42 pages (see pp. 7-8) which Applicant believes may have been distributed by Thoracent, Inc, (see https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRUrl.cfm?lid=5… [cited by applicant]
“Pointer” Endoscopic Marker ADDOBIO Product Brochure; 43 pages (see pp. 7-8) which Applicant believes may have been distributed by Osteonic Co., Ltd. (see http://osteonic.com/eng/product/product_list_view.php?M1=7&M2-72… [cited by applicant]
Combined Search and Examination Report under Sections 17 & 18(3) mailed Mar. 15, 2018 in GB Patent Application No. 1802374.7, 6 pages. [cited by applicant]
Fung et al., Introduction to Bioengineering, World Scientific Publishing, p. 163 (2001). [cited by applicant]
Office Action for U.S. Appl. No. 15/690,178, dated Dec. 11, 2018. [cited by applicant]
Office Action for U.S. Appl. No. 15/690,178, dated Jul. 13, 2018. [cited by applicant]
Office Action for U.S. Appl. No. 15/690,178, dated Sep. 30, 2019. [cited by applicant]
Office Action for U.S. Appl. No. 15/690,178, dated Jul. 24, 2020. [cited by applicant]
Office Action for U.S. Appl. No. 15/690,178, dated Feb. 18, 2022. [cited by applicant]